JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Identification and Functional Characterization of PI3K/Akt/mTOR Pathway-Related lncRNAs in Lung Adenocarcinoma: A Retrospective Study

  • 0The Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang, China.
Cell Journal +

|

February 14, 2024

|

February 14, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Researchers identified seven long non-coding RNAs (lncRNAs) linked to the PI3K/Akt/mTOR pathway, aiding prognosis prediction and immunotherapy optimization in lung adenocarcinoma (LUAD). This discovery enhances understanding of the LUAD immune microenvironment.

Area Of Science

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background

  • Lung adenocarcinoma (LUAD) is a major cause of cancer mortality.
  • Immunotherapy has shown promise in treating LUAD, but patient selection remains a challenge.
  • The PI3K/Akt/mTOR signaling pathway plays a critical role in LUAD development and progression.

Purpose Of The Study

  • To identify long non-coding RNA (lncRNA) signatures related to PI3K/Akt/mTOR pathway regulators in LUAD.
  • To develop prognostic models for LUAD patients undergoing immunotherapy.
  • To explore the association between these lncRNAs, the immune microenvironment, and treatment response.

Main Methods

  • Retrospective analysis using univariate and multivariate Cox regression, and LASSO regression.
  • Identification of prognosis-related lncRNAs and construction of prognostic models.
  • Gene Ontology (GO) and KEGG pathway analyses, followed by immunoassay and drug screening.
  • Validation using the Imvigor210 cohort and analysis of tumor stem cells.

Main Results

  • Seven prognosis-related lncRNAs (AC084757.3, AC010999.2, LINC02802, AC026979.2, AC024896.1, LINC00941, LINC01312) were identified.
  • Prognostic models were developed to predict survival in LUAD patients.
  • KEGG analysis confirmed LUAD's association with the PI3K/Akt/mTOR pathway; three favorable immune pathways were identified.
  • 73 chemotherapy drugs were screened using the pRRophetic algorithm.

Conclusions

  • The identified seven lncRNAs offer valuable insights for predicting LUAD prognosis.
  • These lncRNAs contribute to understanding the immune microenvironment in LUAD.
  • The findings can help optimize immunotherapy strategies for LUAD patients.

Keywords:

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway 01:22

3.6K

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...

lncRNA - Long Non-coding RNAs 02:39

8.6K

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

mTOR Signaling and Cancer Progression 03:03

3.8K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...